Wyllie Jonathan, Niermeyer Susan
The James Cook University Hospital, Middlesbrough, UK.
Semin Fetal Neonatal Med. 2008 Dec;13(6):416-23. doi: 10.1016/j.siny.2008.04.017. Epub 2008 May 27.
Medications are used rarely in newborn resuscitations and are probably justifiable in less than 0.1% of births. Doses used are mainly extrapolated from animal and adult data. Despite this, the drugs used, their order and route of administration have all been sources of controversy for many years. There have been polarised views, often focusing upon adrenaline and sodium bicarbonate and more recently new drugs such as vasopressin have been suggested, once again extrapolating from adult experience. This article examines the sparse data behind the use of any medication at birth and the poor outcome data available. The appropriate decline in the indiscriminate use of volume expansion is considered and balanced by the increasing evidence in favour of delayed clamping of the umbilical cord. Focusing on the basic steps of resuscitation, improving the quality of their application and avoiding relative hypovolaemia, must improve the quality of outcome data. The place of medications in newborn resuscitation should be regarded as experimental and still requires evidence to justify their use especially in premature babies.
药物在新生儿复苏中很少使用,可能仅在不到0.1%的分娩中使用才合理。使用的剂量主要是根据动物和成人数据推断而来。尽管如此,多年来所使用的药物、用药顺序及给药途径一直都是争议的源头。存在两极分化的观点,常常聚焦于肾上腺素和碳酸氢钠,最近又有人提出使用血管加压素等新药,同样也是根据成人经验推断而来。本文审视了出生时使用任何药物背后的稀少数据以及可得的不良结局数据。考虑到随意使用扩容剂的情况应适当减少,并权衡越来越多支持延迟脐带结扎的证据。专注于复苏的基本步骤、提高其实施质量并避免相对性低血容量,必定能改善结局数据的质量。药物在新生儿复苏中的作用应被视为试验性的,仍需要证据来证明其使用的合理性,尤其是在早产儿中。